Cenoalis Corporation

Cenoalis Corporation is a for-profit corporate entity registered to receive federal awards. It appears to specialize in bioinformatics and the development of methods for predicting neoepitopes, which are small protein fragments derived from mutated genes that can trigger an immune response against cancer cells.

Cenoalis Corporation has received multiple sub-awards from the Dana-Farber Cancer Institute, Inc. to develop bioinformatics methods for predicting neoepitopes arising from coding and non-coding regions of the genome. The scope of work involves creating an initial pipeline for neoepitope prediction, continuously improving the accuracy of the prediction methods by incorporating more sequencing and experimental validation data, and developing advanced machine learning algorithms for neoepitope prediction. Additionally, Cenoalis Corporation is tasked with developing a searchable and visualizable web server to provide access to neoepitope information based on the data generated throughout the project. The sub-awards describe the progressive development of neoepitope prediction capabilities and the delivery of a web-based platform to disseminate the resulting data.